Physician profile
Eric Jay Storey
NPI 1205598984
$2,083.01
in general payments reported to CMS, 2019-2025
14 companies · $925 in 2025
The $925 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $354 · 2023: $85.06 · 2024: $718 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $494.18 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $484.31 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $279.00 | 2025 | Epclusa, Livdelzi |
| Dexcom, INC. | $229.59 | 2022-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $188.50 | 2023-2024 | Wegovy |
| Lilly USA, LLC | $145.40 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Xeris Pharmaceuticals, INC. | $94.00 | 2024-2025 | Gvoke Hypopen |
| Genzyme Corporation | $38.82 | 2023 | |
| Hologic Sales and Service, LLC | $33.62 | 2025 | Aptima |
| Tandem Diabetes Care, INC. | $26.86 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Braintree Laboratories, INC. | $21.94 | 2025 | Suflave, Sutab |
| Celltrion USA INC. | $16.86 | 2024 | Vegzelma |
| Madrigal Pharmaceuticals | $15.38 | 2024 | Resmetirom |
| Evoke Pharma, INC. | $14.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Storey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.